


## Sinovac to supply Hep A vaccine to Jiangsu province

11 November 2013 | News | By BioSpectrum Bureau



**Singapore:** Sinovac Biotech, a leading China-based vaccine manufacturer, has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) in 2014 to the pediatric population in Jiangsu Province.

The total volume of the tender is up to 1.8 million doses. As one of the two selected suppliers, Sinovac will supply 900,000 doses of Healive to Jiangsu province.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to be selected once again by the Jiangsu CDC as one of the two suppliers of inactivated hepatitis A vaccine pursuant to the tender for the 2014 EPI. We are advancing our strategy to collaborate with the government agencies to provide top-quality vaccines to prevent and control diseases in China and beyond."

Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. Healive was launched by Sinovac in 2002 in China and is currently available in adult and pediatric dosage forms. In February 2008, the Chinese government included hepatitis A vaccine in its national immunization program.